ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Muscle Invasive Bladder Cancer (MIBC) Clinical Trials Review, H2 2021 Market Report - ResearchAndMarkets.com

October 13, 2021 GMT

DUBLIN--(BUSINESS WIRE)--Oct 13, 2021--

The “Muscle Invasive Bladder Cancer (MIBC) - Global Clinical Trials Review, H2, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.

“Muscle Invasive Bladder Cancer (MIBC) - Global Clinical Trials Review, H2, 2021” provides an overview of Muscle Invasive Bladder Cancer (MIBC) Clinical trials scenario.

This report provides top line data relating to the clinical trials on Muscle Invasive Bladder Cancer (MIBC) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

ADVERTISEMENT

The report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope

  • the report provides a snapshot of the global clinical trials landscape
  • the report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • the report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • the report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • the report provides enrollment trends for the past five years
  • the report provides latest news for the past three months

Clinical Trials Report Coverage

ADVERTISEMENT

  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Muscle Invasive Bladder Cancer (MIBC) to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Muscle Invasive Bladder Cancer (MIBC) to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Muscle Invasive Bladder Cancer (MIBC) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots

Companies Mentioned

  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Merck & Co Inc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Astellas Pharma Inc
  • Pfizer Inc
  • Amgen Inc
  • Apices Soluciones SL
  • BeiGene Ltd

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/wb3kuo

View source version on businesswire.com:https://www.businesswire.com/news/home/20211013005738/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: PHARMACEUTICAL HEALTH ONCOLOGY CLINICAL TRIALS

SOURCE: Research and Markets

Copyright Business Wire 2021.

PUB: 10/13/2021 09:38 AM/DISC: 10/13/2021 09:38 AM

http://www.businesswire.com/news/home/20211013005738/en